A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir

NCT03198884 · clinicaltrials.gov ↗

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

HIV-1-infection

Interventions

DRUG: Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG

Sponsor

Southern Illinois Healthcare Foundation

Collaborators

[object Object]